Patients with acute myocardial infarction (AMI) with thrombus-laden lesions constitute a revascularization challenge. Thrombus and atherosclerotic plaque absorb laser energy; thus, we studied the… (More)
CONTEXT
The development of contrast-induced nephropathy in patients undergoing invasive cardiac procedures is associated with a marked increase in cardiovascular morbidity and mortality. Fenoldopam… (More)
How well absence of coronary artery calcium (CAC) predicts the absence of noncalcified coronary artery plaque (NCAP) has not been elucidated. We conducted a cross-sectional study of 554 outpatients… (More)
We now have at our disposal a variety of new technologies for percutaneous coronary revascularization, including drug-eluting stents (DES), intracoronary radiation therapy, and glycoprotein IIb/IIIa… (More)
Cardiovascular CT represents an important innovation in cardiac imaging as a noninvasive modality for the diagnosis of coronary artery disease. As a screening examination, coronary CT has the ability… (More)
Patients sustaining acute myocardial infarction (AMI) often require urgent percutaneous revascularization within the first 24 h from onset of the infarction due to continuous ischemia and hemodynamic… (More)
Infections associated with percutaneously implanted devices, such as pacemakers, internal cardiac defibrillators, and endovascular prostheses, create difficult and complex clinical scenarios because… (More)
A protocol for using fenoldopam, an FDA-approved intravenous agent for the treatment of severe hypertension with a newly available renal vasodilatory effect, was adopted to prevent radiocontrast… (More)
METHODS From January 2008 to May 2015, a total of 226 consecutive patients with 250 wounds underwent complete angiosome-targeted PTA for only ischemic foot wound and multi-vessel BTK artery disease.… (More)
. Excimer laser coronary angioplasty (ELCA) offers a unique approach to the treatment of bifurcation lesions that continues to present a challenge in percutaneous coronary intervention. Debulking… (More)